IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/24/2023 | $38.00 | Equal Weight | Wells Fargo |
| 5/22/2023 | $71.00 | Buy | Canaccord Genuity |
| 3/31/2023 | $56.00 | Buy | Needham |
| 3/1/2023 | Outperform | TD Cowen | |
| 3/1/2023 | Outperform | Cowen | |
| 11/15/2022 | $65.00 | Buy | Guggenheim |
| 9/14/2022 | $36.00 | Overweight | Cantor Fitzgerald |
| 9/7/2022 | $37.00 | Buy | Stifel |
| 7/18/2022 | $40.00 | Buy | H.C. Wainwright |
| 10/11/2021 | $46.00 | Outperform | SVB Leerink |
15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)
EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)
S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
POSASR - DICE Therapeutics, Inc. (0001645569) (Filer)
POS AM - DICE Therapeutics, Inc. (0001645569) (Filer)
8-K - DICE Therapeutics, Inc. (0001645569) (Filer)
SC 14D9/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC TO-T/A - DICE Therapeutics, Inc. (0001645569) (Subject)
INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new
INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ:DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third q
NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and DICE Therapeutics, Inc. (NASDAQ:DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases," sai
SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced that management will host a research & development (R&D) day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY. The event will highlight progress on DICE's clinical-stage and discovery programs as well as key aspects of the company's DELSCAPE platform. A live and archived webcast of the R&D Day will be accessible under "News & Events" in the Investor
First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasisTopline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chr
SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET. A live and archived webcast of the fireside chat will be accessible under "News & Events" in the Investors section of the company's website for 90 days after the event. About DICE Therapeutics, Inc.DICE Thera
SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET. A live and archived webcast of the fireside chat will be accessible under "News & Events" in the Investors section of the company's website for 90 days after the event. About DICE Therapeutics, Inc.DICE Th
IND application for DICE's lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline data in healthy volunteers expected in 2H 2023Ended 2022 with $574.2 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology pla
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA. Details of the presentation are as follows: Title: DC-806, an ora
INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new
Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806 Data supports further development of DC-806 as potential best-in-class oral agent for psoriasis; DC-806 is expected to advance into a Phase 2b clinical trial in the first half of 2023 Company to host conference cal
ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv
Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board. "Mary, Lisa and Mittie are e
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
Wells Fargo initiated coverage of DICE Therapeutics with a rating of Equal Weight and set a new price target of $38.00
Canaccord Genuity initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $71.00
Needham initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $56.00
TD Cowen initiated coverage of DICE Therapeutics with a rating of Outperform
Cowen initiated coverage of DICE Therapeutics with a rating of Outperform
Guggenheim initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $65.00
Cantor Fitzgerald initiated coverage of DICE Therapeutics with a rating of Overweight and set a new price target of $36.00
Stifel initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $37.00
H.C. Wainwright initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $40.00
SVB Leerink initiated coverage of DICE Therapeutics with a rating of Outperform and set a new price target of $46.00
SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13G - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13G - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13G - DICE Therapeutics, Inc. (0001645569) (Subject)
SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)